.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP51_SofosbuvirAndLedipasvir.SofosbuvirAndLedipasvir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP51_SofosbuvirAndLedipasvir.SofosbuvirAndLedipasvir| name: | SofosbuvirAndLedipasvir |
| ATC code: | J05AP51 | route: | oral |
| n-compartments | 2 |
Sofosbuvir and ledipasvir is a fixed-dose combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, and ledipasvir is an inhibitor of the HCV NS5A protein. This combination is approved for use in adults and children above 3 years for several HCV genotypes.
Pharmacokinetic parameters reported for healthy adult volunteers after administration of a single fixed-dose oral tablet containing ledipasvir 90 mg and sofosbuvir 400 mg (as Harvoni).